Research Establishment for Electronic Publication, 2023.
سنة النشر:
2023
الوصف:
Chronic pain is regarded as a global public health issue which significantly affects the quality of life. Fibromyalgia is the most widespread chronic pain condition. It has grown to alarming proportions in terms of impairment, use of health and social resources, and impact on general and specialty care systems. Fibromyalgia is characterized by persistent, widespread musculoskeletal pain that is frequently accompanied by additional signs and symptoms such exhaustion, gastrointestinal problems, and changes in mood and sleep. Fibromyalgia is thought to affect approximately 2%-8% of people worldwide. Diagnostic criteria for fibromyalgia include presence of pain on both sides of the body, above and below the waist, present for at least three months, the presence of at least 11 out of a possible 18 tender points, and the lack of any other condition that could explain the pain better. Fibromyalgia affects women more commonly than men. Diagnosis and treatment of fibromyalgia can be challenging due to its complexity and also due to the absence of specific markers and laboratory diagnostics. Fibromyalgia is a contentious illness. Multidisciplinary approach is best for the treatment and management of fibromyalgia. Antidepressants and neuromodulating antiepileptics, which only presently include duloxetine, milnacipran, and pregabalin, play a significant role in treating fibromyalgia while most nonsteroidal anti-inflammatory medications and opioids offer very modest benefits. Additionally, pharmacological therapy should be combined with nonpharmacological treatments including exercise and physiotherapy among others. The purpose of this research is to review the available information about prevalence, diagnostic challenges and management of fibromyalgia
